Solving Kids Cancer Inc is located in New York, NY. The organization was established in 2007. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. As of 12/2023, Solving Kids Cancer Inc employed 5 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Solving Kids Cancer Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Solving Kids Cancer Inc generated $641.1k in total revenue. The organization has seen a slow decline revenue. Over the past 9 years, revenues have fallen by an average of (1.5%) each year. All expenses for the organization totaled $1.2m during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (1.3%) per year over the past 9 years. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Solving Kids Cancer Inc has awarded 39 individual grants totaling $5,084,750. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
TO MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS.
Describe the Organization's Program Activity:
Part 3 - Line 4a
SKC AND OUR ADVISORS SURVEY, ACTIVELY DISCUSS, AND PRIORITIZE THE AREAS OF GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. (1) THE PH I TITAN CLINICAL TRIAL IS PROVIDING AN EFFECTIVE TARGETED DRUG FOR CHILDREN WITH ALK MUTATIONS IN FRONTLINE TREATMENT WHEN NEWLY DIAGNOSED AND IS GENERATING CRITICAL DATA TOWARDS AN APPROVAL FOR USE AS A STANDARD OF CARE. WORKING TOWARDS HAVING THIS BE ONE OF THE FIRST TARGETED AGENTS BECOMING APPROVED FOR HR NB AND UTILIZED AS A COMBINATION THERAPY STRATEGY, MAKING A SIGNIFICANT IMPACT ON OVERALL SURVIVAL. (2) OUR COLLABORATION WITH THE NATIONAL CANCER INSTITUTE TO VALIDATE AND DEVELOP AN IMMUNOTHERAPY TREATMENT FOR CHILDREN WITH ETMR AND MEDULLOBLASTOMA BRAIN TUMORS USING A T CELL CAR TO TARGET GPC2 IS THE FIRST EVER IMMUNOTHERAPY RESEARCH PROGRAM SPECIFIC FOR ETMR BRAIN TUMORS. IF THE RESULTS ARE POSITIVE THIS WORK WILL BE RAPIDLY TRANSLATED INTO A CLINICAL TRIAL TO INCLUDE CHILDREN WITH ETMR AS WELL AS MEDULLOBLASTOMA USING THIS CUTTING-EDGE IMMUNOTHERAPY. (3) THE PH I CLINICAL TRIAL USING A TRIPLET COMBINATION HAS BEEN A LIFELINE FOR CHILDREN WITH NEUROBLASTOMA WHO RELAPSE AND THE STUDY HAS BEEN SO SUCCESSFUL THAT IT WILL STAY OPEN TO ACCRUE EVEN MORE PATIENTS THAN ORIGINALLY PLANNED. WHILE THE CLINICAL TRIAL IS PROVIDING TREATMENT BENEFIT TO PATIENTS, THE TRIAL IS GENERATING VERY IMPORTANT DATA THAT CAN BE USED TO FURTHER ADVANCE THIS TRIPLE TREATMENT COMBINATION INTO MORE POINTS IN THE TREATMENT CONTINUUM FOR EVEN GREATER PATIENT BENEFIT. (4) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (5) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (6) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (7) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (8) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. (9) WE ARE PLANNING A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Scott Kennedy Executive Di | Officer | 40 | $142,520 |
Khalil Barrage Director | Trustee | 2 | $0 |
Hearn Jay Cho Director | Trustee | 2 | $0 |
Diala Tabet Director | Trustee | 2 | $0 |
Lindy Gad Director | Trustee | 2 | $0 |
John London Chair | OfficerTrustee | 2 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $207,063 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $450,513 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $657,576 |
Total Program Service Revenue | $0 |
Investment income | $71,862 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | -$88,370 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $641,068 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $466,773 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $45,000 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $148,000 |
Compensation of current officers, directors, key employees. | $14,800 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $193,509 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $30,024 |
Payroll taxes | $25,388 |
Fees for services: Management | $0 |
Fees for services: Legal | $0 |
Fees for services: Accounting | $53,543 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $46,200 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $38,113 |
Advertising and promotion | $13,306 |
Office expenses | $1,778 |
Information technology | $4,904 |
Royalties | $0 |
Occupancy | $17,618 |
Travel | $7,349 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $0 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $6,377 |
All other expenses | $0 |
Total functional expenses | $1,154,712 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $289,435 |
Savings and temporary cash investments | $278,457 |
Pledges and grants receivable | $65,000 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $5,081 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $1,302,883 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $134,467 |
Total assets | $2,075,323 |
Accounts payable and accrued expenses | $12,668 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $132,999 |
Total liabilities | $145,667 |
Net assets without donor restrictions | $439,540 |
Net assets with donor restrictions | $1,490,116 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $2,075,323 |
Over the last fiscal year, Solving Kids Cancer Inc has awarded $465,796 in support to 6 organizations.
Grant Recipient | Amount |
---|---|
COLUMBIA UNIVERSITY PURPOSE: CANCER RESEARCH | $5,068 |
THE REGENTS OF THE UNIVERSITY OF CA PURPOSE: CANCER RESEARCH | $150,000 |
WEILL MEDICAL COLLEGE OF CORNELLUNIVERSITY PURPOSE: CANCER RESEARCH | $6,228 |
CHILDREN'S HOSPITAL OF PHILADELPHIA PURPOSE: CANCER RESEARCH | $162,500 |
NATIONAL CANCER INSTITUTE PURPOSE: CANCER RESEARCH | $47,000 |
THE SWIFTY FOUNDATION PURPOSE: CANCER RESEARCH | $95,000 |